Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060672105> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2060672105 endingPage "P57" @default.
- W2060672105 startingPage "P57" @default.
- W2060672105 abstract "Sublingual fentanyl tablet (Abstral®) is a rapid-onset formulation under evaluation in the United States and approved in Europe for management of breakthrough pain in opioid-tolerant patients with cancer. Understanding whether multiple lower-dose tablets yield the same pharmacokinetics as a single tablet containing an equivalent total dose may aid physicians and be more convenient for patients, particularly during dose titration. This open-label, randomized, single-dose, 3-period crossover study compared bioavailability of sublingual fentanyl 800 mcg administered as one 800-mcg tablet, two 400-mcg tablets, or four 200-mcg tablets, administered by placing on the floor of the mouth directly under the tongue until completely dissolved. In total, 36 patients (mean age, 27.3 y; 53% female; 83% white) were randomized into 6 dosing sequences, with 7 days between doses. Naltrexone 50 mg tablets were administered concomitantly to reduce potential for respiratory-related adverse events (AEs). Blood samples for pharmacokinetic assessments were taken predose through 30 hours postdose. Rate and extent of exposure of sublingual fentanyl administered as two 400-mcg tablets and four 200-mcg tablets, measured by mean Cmax, AUC(0-t), and AUC(0-∞), were 98-112% and 97-113%, respectively, of the corresponding measures for one 800-mcg tablet. Tmax and t½ were similar between treatments. These data indicate bioequivalence of sublingual fentanyl administered as one 800-mcg tablet, two 400-mcg tablets, and four 200-mcg tablets. All doses were generally well tolerated. AEs occurred in 21% (7/33), 28% (9/32), and 24% (2/33) of subjects receiving the single 800-mcg tablet, two 400-mcg tablets, and four 200-mcg tablets, respectively. The most common AEs included nausea, vomiting, dizziness, headache, fatigue, and myalgia. Due to dose-proportional pharmacokinetics, multiple lower-dose sublingual fentanyl tablets can be administered to achieve the same effects as a smaller number of larger-dose tablets. Editorial and writing support was provided by Synchrony Medical LLC, funded by ProStrakan Group." @default.
- W2060672105 created "2016-06-24" @default.
- W2060672105 creator A5012857513 @default.
- W2060672105 creator A5064159896 @default.
- W2060672105 creator A5073025573 @default.
- W2060672105 date "2011-04-01" @default.
- W2060672105 modified "2023-09-25" @default.
- W2060672105 title "Pharmacokinetics of 800 mcg of sublingual fentanyl tablets, administered as one 800-mcg tablet, two 400-mcg tablets, or four 200-mcg tablets, in healthy volunteers" @default.
- W2060672105 doi "https://doi.org/10.1016/j.jpain.2011.02.233" @default.
- W2060672105 hasPublicationYear "2011" @default.
- W2060672105 type Work @default.
- W2060672105 sameAs 2060672105 @default.
- W2060672105 citedByCount "0" @default.
- W2060672105 crossrefType "journal-article" @default.
- W2060672105 hasAuthorship W2060672105A5012857513 @default.
- W2060672105 hasAuthorship W2060672105A5064159896 @default.
- W2060672105 hasAuthorship W2060672105A5073025573 @default.
- W2060672105 hasBestOaLocation W20606721051 @default.
- W2060672105 hasConcept C112705442 @default.
- W2060672105 hasConcept C142724271 @default.
- W2060672105 hasConcept C181389837 @default.
- W2060672105 hasConcept C197934379 @default.
- W2060672105 hasConcept C204787440 @default.
- W2060672105 hasConcept C22979827 @default.
- W2060672105 hasConcept C27081682 @default.
- W2060672105 hasConcept C2777288759 @default.
- W2060672105 hasConcept C2779350572 @default.
- W2060672105 hasConcept C2781072394 @default.
- W2060672105 hasConcept C42219234 @default.
- W2060672105 hasConcept C42404028 @default.
- W2060672105 hasConcept C71924100 @default.
- W2060672105 hasConcept C87813604 @default.
- W2060672105 hasConcept C98274493 @default.
- W2060672105 hasConceptScore W2060672105C112705442 @default.
- W2060672105 hasConceptScore W2060672105C142724271 @default.
- W2060672105 hasConceptScore W2060672105C181389837 @default.
- W2060672105 hasConceptScore W2060672105C197934379 @default.
- W2060672105 hasConceptScore W2060672105C204787440 @default.
- W2060672105 hasConceptScore W2060672105C22979827 @default.
- W2060672105 hasConceptScore W2060672105C27081682 @default.
- W2060672105 hasConceptScore W2060672105C2777288759 @default.
- W2060672105 hasConceptScore W2060672105C2779350572 @default.
- W2060672105 hasConceptScore W2060672105C2781072394 @default.
- W2060672105 hasConceptScore W2060672105C42219234 @default.
- W2060672105 hasConceptScore W2060672105C42404028 @default.
- W2060672105 hasConceptScore W2060672105C71924100 @default.
- W2060672105 hasConceptScore W2060672105C87813604 @default.
- W2060672105 hasConceptScore W2060672105C98274493 @default.
- W2060672105 hasIssue "4" @default.
- W2060672105 hasLocation W20606721051 @default.
- W2060672105 hasOpenAccess W2060672105 @default.
- W2060672105 hasPrimaryLocation W20606721051 @default.
- W2060672105 hasRelatedWork W2349338867 @default.
- W2060672105 hasRelatedWork W2351830309 @default.
- W2060672105 hasRelatedWork W2353450705 @default.
- W2060672105 hasRelatedWork W2356698425 @default.
- W2060672105 hasRelatedWork W2357220270 @default.
- W2060672105 hasRelatedWork W2374069256 @default.
- W2060672105 hasRelatedWork W2387133671 @default.
- W2060672105 hasRelatedWork W2387566090 @default.
- W2060672105 hasRelatedWork W2392383498 @default.
- W2060672105 hasRelatedWork W48952282 @default.
- W2060672105 hasVolume "12" @default.
- W2060672105 isParatext "false" @default.
- W2060672105 isRetracted "false" @default.
- W2060672105 magId "2060672105" @default.
- W2060672105 workType "article" @default.